Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. (Q39189394)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 December 2014

edit

Language	Label	Description	Also known as
English	Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.	scientific article published on 23 December 2014

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

retrieved

9 September 2017

title

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

retrieved

9 September 2017

main subject

lymphocyte

0 references

chemotherapy

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author

David Lorente

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

Joaquin Mateo

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

Arnoud J Templeton

series ordinal

3

object named as

A J Templeton

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

author name string

Z Zafeiriou

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

D Bianchini

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

R Ferraldeschi

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

A Bahl

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

L Shen

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

Z Su

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

O Sartor

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

J S de Bono

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

publication date

23 December 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

retrieved

9 September 2017

published in

Annals of Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

volume

26

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

page(s)

750-755

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

cites work

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Hallmarks of Cancer: The Next Generation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU587

retrieved

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU587

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

Fatcat ID

release_o74rge3hnjbcpi7b4fhrljx5fa

0 references

PubMed publication ID

25538172

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25538172

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25538172%20AND%20SRC:MED&resulttype=core&format=json

retrieved

12 June 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39189394&oldid=1521636968"